Just some news I've read today.
They have FDA approval which has had a healthy effect on their share price. Also They have announced that they have secured reimbursement for the Freestyle Libre system in the UK. Available on the NHS from 1st November 2017 (subject to local health economy approval).
I'm trying to understand exactly what that means and what the effect will be for say type I and type II users. The bit in brackets indicates that it will depend on the health authority where we live.
Dear FreeStyle user,
This is a reminder for your invitation by the Department of Health to provide comments regarding the NDSS listing of FreeStyle Libre.
As a FreeStyle user, your opinion is important to this process.
Stakeholder comments will play an important role in the independent Advisory Committee’s deliberations. The Department of Health encourages dissemination of this Stakeholder Consultation to all individuals or parties that you may identify as having an interest.
The consultation process is now open and comments can be submitted until 17 July 2017.
you might want to have a read of these:
Libre on prescription:
I wonder if the increase in sales might have a beneficial effect on the price of the sensors?
I can't see sales going up by much in the near future...........
someone will have to pay for the builk discounts the CCGs demand
I was thinking worldwide sales and more specifically the U.S
I'm unaware of a sales increase of some company's product help reduce the cost of another product
They are $92.50 per sensor here in Australia, so if the they do subsidise these through the NDSS it will be great help.I wait with bated breath. LOL Just to see how the prices of a sensor in the U.S. compares with the U.K.
They are $92.50 per sensor here in Australia,
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?